ランキングに戻る

Surgery Partners, Inc. (SGRY)

NEUTRAL
HealthcareMedical Care FacilitiesUnited States

ファンダメンタル

54

株価

$13.99

時価総額

$1.90B

パート1 · 企業の価値

概要

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

貸借対照表と流動性

売上高

$3.37B

直近12か月(2026/6/30まで)

純利益

$-89M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$196M

自己資本合計

$1.71B

負債合計

$4.99B

流動比率

1.95

利払い倍率

-

負債/EBITDA

7.18

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

General case適正価値

適正価値

$17.17

現在株価

$13.99

安全マージン

+18.5%

適正価値レンジ

$14.82 - $19.53

推定方法

Analyst price target:$18.73
Discounted cash flow (DCF):$17.06
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):$11.29
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$70.60
Revenue multiple:Not enough data to compute it
アナリスト・コンセンサス:強い買い (14B / 4H / 0S)
直近の決算サプライズ:+68.07%

バリュエーション指標

P/E レシオ

-

ROE

-4.5%

P/B レシオ

1.09

P/FCF

9.74

粗利益率

-

ROIC

4.1%

収益性レーダー

Value Creation (Economic Moat)

ROIC

4.1%

WACC

4.9%

ROIC − WACC

-0.9 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

ファンダメンタル分析基準

合格(12)

  • P/FCF 9.74
  • P/B Ratio 1.09
  • Debt/Equity ratio
  • Operating Margin 11.4%
  • Positive Free Cash Flow
  • Current Ratio
  • Revenue Growth 5Y 12.2%
  • Analyst Consensus 78% Buy
  • Earnings Surprise avg 14.8%
  • Share Dilution 1.0%
  • Net Margin Trend -2.6% vs -5.6%
  • Piotroski F-Score 5/9

不合格(9)

  • EPS shows upward trend
  • Price CAGR -0.87%
  • ROIC 4.1%
  • CapEx intensity
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Fairly valued)
  • ROE -5.3%

データなし(6)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-スコア

5/9

まちまちのシグナル:一部の領域に注意が必要

score
criteria

利益の質

-

低品質:会計処理を調査してください

株式希薄化

1.0%

株式数は安定している

ガバナンス

経営陣

氏名役職年齢
Mr. J. Eric EvansCEO & Director48
Mr. David T. Doherty CPAExecutive VP & CFO53
Ms. Jennifer B. Baldock J.D.Executive VP and Chief Administrative & Development Officer54
Ms. Marissa A. BrittenhamExecutive VP & Chief Strategy Officer40
Mr. W. Trent WebbDivision President South45
Mr. Justin R. OppenheimerExecutive VP & COO40
Mr. Jon FredricksonSenior VP & Chief Information Officer-
Ms. Roxanne WomackSenior VP & Chief Compliance Officer-
Mr. Spencer ClarkGeneral Counsel & Senior VP-
Ms. Danielle BurkhalterExecutive VP & Chief Human Resources Officer40

監査リスク

9

取締役会リスク

6

報酬リスク

4

株主権利リスク

8

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

Latest News

Recent headlines for SGRY, sourced from Markets Gazette.

  • 3/3/2026NEGATIVE
    Surgery Partners Stock Hits 52-Week Low - Here's Why

    Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.

  • 2/23/2026NEGATIVE
    Surgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million

    Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.

via Markets Gazette